Is actemra used to treat severe cases of covid 19?

How is Actemra used in severe COVID-19 cases?

Actemra (tocilizumab) is approved for treating cytokine storms in hospitalized adults with severe COVID-19 who require supplemental oxygen or mechanical ventilation. It works by blocking interleukin-6 receptors to calm an excessive immune response.

What clinical data supports its use?

The RECOVERY trial showed that tocilizumab plus standard care reduced 28-day mortality in patients needing oxygen or ventilation. The REMAP-CAP trial found that tocilizumab and sarilumab improved outcomes in critically ill patients. Both trials focused on patients already receiving corticosteroids.

When does Actemra’s exclusivity expire?

Actemra’s U.S. patent protection runs through 2030. Biosimilars are expected to enter the market shortly after that date.

What side effects are patients asking about?

Common concerns include higher risk of serious infections, gastrointestinal perforations, and elevated liver enzymes. Patients also query about long-term effects after receiving one-time doses during acute COVID-19 illness.

Can biosimilars enter before patent expiry?

No. Current U.S. regulatory rules require patents to expire before biosimilar approval and launch. Challenges to Actemra’s patents have so far failed.

Who makes Actemra?

Genentech, a Roche company, is the originator manufacturer. DrugPatentWatch.com tracks its patent portfolio and potential biosimilar competitors.